丹红化瘀口服液对视网膜中央静脉阻塞细胞因子网络的调节作用

符郁; 郭翠玲

doi:10.13422/j.cnki.syfjx.2017180210

您当前的位置：

首页 >

文章列表页 >

丹红化瘀口服液对视网膜中央静脉阻塞细胞因子网络的调节作用

临床 | 更新时间：2024-01-04

- 丹红化瘀口服液对视网膜中央静脉阻塞细胞因子网络的调节作用
- Regulating Effect of Danhong Huayu Oral Solution on Cytokine Network of Retinal Central Venous Obstruction
- 中国实验方剂学杂志 2017年23卷第18期页码：210-215
- 作者机构：
- 作者简介：
- 基金信息：
  
  海南省医学科技攻关项目（201602077）
- DOI：10.13422/j.cnki.syfjx.2017180210
  中图分类号： R276.7
- 纸质出版日期：2017
- 稿件说明：
移动端阅览
符郁, 郭翠玲. 丹红化瘀口服液对视网膜中央静脉阻塞细胞因子网络的调节作用[J]. 中国实验方剂学杂志, 2017,23(18):210-215.

FU Yu, GUO Cui-ling. Regulating Effect of Danhong Huayu Oral Solution on Cytokine Network of Retinal Central Venous Obstruction[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(18): 210-215.
符郁, 郭翠玲. 丹红化瘀口服液对视网膜中央静脉阻塞细胞因子网络的调节作用[J]. 中国实验方剂学杂志, 2017,23(18):210-215. DOI： 10.13422/j.cnki.syfjx.2017180210.

FU Yu, GUO Cui-ling. Regulating Effect of Danhong Huayu Oral Solution on Cytokine Network of Retinal Central Venous Obstruction[J]. Chinese journal of experimental traditional medical formulae, 2017, 23(18): 210-215. DOI： 10.13422/j.cnki.syfjx.2017180210.

摘要

目的：观察丹红化瘀口服液治疗视网膜中央静脉阻塞气滞血瘀证的临床疗效及对房水和血清细胞因子的调节作用。方法：将144例患者就诊先后采用区组随机分为对照组和观察组。对照组采用雷珠单抗注射液，0.05 mL/次，1次/月，共3次。观察组口服丹红化瘀口服液，20 mL/次，3次/d。连续服用3个月。采用国际标准视力表检查最佳矫正视力（BCVA），进行气滞血瘀证评分，测量中心凹厚度（CMT），进行荧光素眼底血管造影记录视网膜血管渗漏面积、视网膜平均循环时间（RCT）和视网膜毛细血管无灌注区面积，均在治疗前后各评价1次。检测第1次和第3次手术前房水血管内皮生长因子（VEGF）和肿瘤坏死因子-α（TNF-α）水平，检测治疗前后血清VEGF，TNF-α，单核细胞趋化蛋白-1（MCP-1）和可溶性细胞间黏附分子-1（ICAM-1）。结果：观察组BCVA疗效总有效率为97.06%，高于对照组的85.07%（χ2=5.985，P<0.05）；观察组黄斑水肿疗效总有效率为94.12%，高于对照组的80.6%（χ2=5.605，P<0.05）；观察组血管渗漏面积和毛细血管无灌注区面积均小于对照组（P<0.01），RCT时间缩短于对照组（P<0.01）；观察组BCVA高于对照组，CMT小于对照组，气滞血瘀证评分低于对照组（P<0.01）；第3次手术前观察组房水VEGF和TNF-α水平均低于对照组（P<0.01）；治疗后观察组血清VEGF，TNF-α，MCP-1和ICAM-1水平均低于对照组（P<0.01）。结论：丹红化瘀口服液联合雷珠单抗注射能提高RVO患者的视力，并能调节房水VEGF，TNF-α和血清VEGF，TNF-α，MCP-1，ICAM-1等细胞因子。

Abstract

Objective: To observe the clinical effect of Danhong Huayu oral solution in treating retinal central venous obstruction Qi stagnation and blood stasis syndrome and its effect in regulating humoraqueus and serum cytokines.Method: One hundred and forty-four patients with uremia were randomly divided into control group and observation group by random number table. Patients in control group were injected with Leizhu monoclonal antibody

0.05 mL/time

1 time/1 month

for 3 times in total. In addition to the therapy of control group

patients in observation group were also given Danhong Huayu oral solution

20 mL/time

3 times/day. The treatment lasted for 3 months. The best corrected vision acuity (BCVA) was detected by the international standard visual acuity chart

and Qi stagnation and blood stasis syndromes were scored

the central macular thickness(CMT) traditional Chinese medicine was detected. And retinal vascular leakage area

mean retinal cycle time (RCT)

and retinal capillary no-perfusion area were recorded by fluorescein fundus angiography before and after treatment. Before the 3th and 5th surgery

levels of vascular endothelial growth factor (VEGF) and tumor necrosis factor-α (TNF-α) in humoraqueus

and VEGF

TNF-α

monocyte chemoattractant protein-1 (MCP-1) and soluble intercellular adhesion molecule-1 (ICAM-1) in serum were detected.Result: The total effect rate of BCVA in observation group was 97.06%

which higher than 85.07% in control group (χ2=5.985

P<0.05). The total effect rate of macular edema in observation group was 94.12%

which was higher than 80.60% in control group (χ2=5.605

P<0.05). Vascular leakage area and capillaries no-perfusion area in observation group were lower than those in observation group (P<0.01). RCT was shorter than that in observation group (P<0.01). BCVA was higher than that in observation group

CMT was lower than that in observation group

and score of Qi stagnation and blood stasis syndrome was lower than that in observation group (P<0.01). And before the 1st and the 3th surgeries

levels of VEGF and TNF-α in humoraqueus and VEGF

TNF-α

MCP-1 and ICAM-1 in serum were lower than those in observation group (P<0.01).Conclusion: Danhong Huayu oral solution combined with Leizhu monoclonal antibody can improve vision

and regulate cytokine networks of VEGF and TNF-α in humoraqueus and VEGF

TNF-α

MCP-1 and ICAM-1 in serum.

关键词

Keywords

references

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

养血化斑汤治疗斑块型银屑病血燥证

葛脾煎剂调控单核细胞趋化蛋白-1水平逆转早期糖尿病肾病的实验研究

肿瘤坏死因子-中药小分子抑制剂的计算机虚拟筛选

补肾方对实验性自身免疫性脑脊髓炎小鼠T辅助细胞1,17和调节性T细胞的影响